Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

News Daily News

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

January 23, 2025

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

December 05, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

News Daily News

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

July 03, 2023

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

January 21, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.